Online inquiry

IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9895MR)

This product GTTS-WQ9895MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets pcrV gene. The antibody can be applied in Cystic Fibrosis (CF) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9895MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14515MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ10961MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ4582MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ738MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ6563MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ10019MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ12314MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ1569MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW